[Federal Register Volume 75, Number 217 (Wednesday, November 10, 2010)]
[Notices]
[Page 69091]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-28373]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, Office of Biotechnology Activities; 
Notice of Meeting

    There will be a workshop entitled ``Retroviral and Lentiviral 
Vectors for Long-Term Gene Correction: Clinical Challenges in Vector 
and Trial Design.'' The meeting will be open to the public; attendance 
is limited to space available. Individuals who plan to attend and need 
special assistance, such as sign language interpretation or other 
reasonable accommodations, should notify the Contact Person listed 
below in advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: December 9, 2010.
    Time: 8 a.m. to 5:30 p.m.
    Date: December 10, 2010.
    Time: 8 a.m. to 1 p.m.
    Agenda: The Office of Biotechnology Activities (OBA), NIH 
Recombinant DNA Advisory Committee and the European Network for the 
Advancement of Clinical Gene Transfer (CliniGene) will host a 
workshop on Retroviral and Lentiviral Vectors for Long-Term Gene 
Correction: Clinical Challenges in Vector and Trial Design at the 
Bethesda Marriott on December 9 and 10, 2010. The meeting will cover 
the following topics: Developments in retrovirus and lentivirus 
integration and insertional mutagenesis research, including non-
enhancer mediated mechanisms of insertional mutagenesis; 
modifications to retroviral and lentiviral vectors to enhance their 
safety; research on in vitro and animal models to evaluate the 
safety of human gene transfer; and ethical issues in the design of 
new clinical trials. The agenda is posted to OBA's Web site: http://oba.od.nih.gov/rdna_rac/rac_meetings.html. Please check the 
meeting agenda for more information.
    Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, 
Maryland 20814.
    Contact Person: Chezelle George, Program Assistant, Office of 
Science Policy, Office of Biotechnology Activities, National 
Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 
20892, 301-496-9838, 301-496-9839, <a href="/cdn-cgi/l/email-protection#bddad8d2cfdad8defdd0dcd4d193d3d4d593dad2cb"><span class="__cf_email__" data-cfemail="3255575d40555751725f535b5e1c5c5b5a1c555d44">[email protected]</span></a>.
    Any interested person may file written comments with the panel 
by forwarding the statement to the Contact Person listed on this 
notice. The statement should include the name, address, telephone 
number and, when applicable, the business or professional 
affiliation of the interested person. Background information may be 
obtained by contacting NIH OBA by e-mail <a href="/cdn-cgi/l/email-protection#dcb3bebd9cb3b8f2b2b5b4f2bbb3aa"><span class="__cf_email__" data-cfemail="b0dfd2d1f0dfd49eded9d89ed7dfc6">[email protected]</span></a>


    Dated: November 1, 2010.
Jacqueline Corrigan-Curay,
Acting Director, Office of Biotechnology Activities, National 
Institutes of Health.
[FR Doc. 2010-28373 Filed 11-9-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>